Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse af blærekemoterapi i stedet for kirurgi for lavrisiko blærekræft (CALIBER)

4. november 2026 opdateret af: Institute of Cancer Research, United Kingdom

CALIBER - En fase II randomiseret gennemførlighedsundersøgelse af kemoresektion og kirurgisk behandling ved lavrisiko ikke-muskelinvasiv blærekræft

Patients diagnosed with low risk non-muscle invasive bladder cancer (NMIBC) are at risk of frequent low grade recurrence, which usually necessitates surgical intervention under general anaesthetic. This multicentre study aims to establish the short term efficacy of chemoresection using chemotherapy within the bladder for the treatment of NMIBC.

Should the levels of complete response following chemoresection meet predefined criteria, a larger phase III trial would be developed to assess longer term disease related endpoints, with the aim of standardising management of recurrent low risk NMIBC and potentially removing the need for over a thousand patients each year to undergo surgery.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

CALIBER is a two stage phase II, multicentre, randomised controlled trial (RCT). A control group has been included to provide prospective data about surgical management and outcomes and assess feasibility of recruitment to a randomised study.

Stage 1: 80 patients will be recruited with treatment allocated 2:1 by randomisation between chemoresection and surgical management.

Stage 2: If the stop/go activity criteria at the end of stage 1 indicate that recruitment should continue, 9 additional participants will be recruited, all of whom will receive chemoresection.

Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg Mitomycin C (MMC) as outpatients. This treatment will be delivered via catheter under local anaesthetic.

Patients assigned to the surgical management group will receive the standard surgical management in use at their hospital for treatment of recurrence which may include a single post-operative installation of 40mg MMC within 24 hours.

All participants will be followed up at 3 weeks from the start of treatment (ie at time of final MMC instillation for chemoresection group) and each will receive a cystoscopy three months from the end of treatment to assess response, in accordance with European Association of Urology (EAU) guidelines.

Subsequent cystoscopic follow up will take place 12 months after treatment if recurrence-free at 3 months and then annually.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

82

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • London, Det Forenede Kongerige, NW1 2BU
        • University College Hospital
      • Manchester, Det Forenede Kongerige, M23 9LT
        • Wythenshawe Hospital
      • Manchester, Det Forenede Kongerige, M20 2LR
        • Withington Hospital
    • Cheshire
      • Macclesfield, Cheshire, Det Forenede Kongerige, SK10 3BL
        • Macclesfield District General Hospital
    • Cleveland
      • Middlesbrough, Cleveland, Det Forenede Kongerige, TS4 3BW
        • James Cook University Hospital
    • Cumbria
      • Whitehaven, Cumbria, Det Forenede Kongerige, CA28 8JG
        • West Cumberland Hospital
    • Devon
      • Exeter, Devon, Det Forenede Kongerige, EX2 5DW
        • Royal Devon and Exeter Hospital
      • Plymouth, Devon, Det Forenede Kongerige, PL6 8DH
        • Derriford Hospital
    • Dorset
      • Bournemouth, Dorset, Det Forenede Kongerige, BH7 7DW
        • Royal Bournemouth Hospital
      • Dorchester, Dorset, Det Forenede Kongerige, DT1 2JY
        • Dorset County Hospital
    • England
      • Carlisle, England, Det Forenede Kongerige, CA2 7HY
        • Cumberland Infirmary
    • Essex
      • Chelmsford, Essex, Det Forenede Kongerige, CM1 5ET
        • Broomfield Hospital
      • Harlow, Essex, Det Forenede Kongerige, CM20 1QX
        • Princess Alexandra Hospital
    • Gloucestershire
      • Cheltenham, Gloucestershire, Det Forenede Kongerige, GL53 7AN
        • Cheltenham General Hospital
      • Gloucester, Gloucestershire, Det Forenede Kongerige, GL1 3NN
        • Gloucestershire Royal Hospital
    • Greater Manchester
      • Manchester, Greater Manchester, Det Forenede Kongerige, OL1 2JH
        • Royal Oldham Hospital
    • Hampshire
      • Basingstoke, Hampshire, Det Forenede Kongerige, RG24 9NA
        • Basingstoke and North Hampshire Hospital
      • Southampton, Hampshire, Det Forenede Kongerige, SO16 6YD
        • Southampton General Hospital
    • Herefordshire
      • Hereford, Herefordshire, Det Forenede Kongerige, HR1 2ER
        • Hereford County Hospital
    • Kent
      • Dartford, Kent, Det Forenede Kongerige, DA2 8DA
        • Darent Valley Hospital
      • Gillingham, Kent, Det Forenede Kongerige, ME7 5NY
        • Medway Maritime Hospital
    • Lancashire
      • Preston, Lancashire, Det Forenede Kongerige, PR2 9HT
        • Royal Preston Hospital
    • Leicestershire
      • Leicester, Leicestershire, Det Forenede Kongerige, LE5 4PW
        • Leicester General Hospital
    • Middlesex
      • Harrow, Middlesex, Det Forenede Kongerige, HA1 3UJ
        • Northwick Park Hospital
    • Oxfordshire
      • Headington, Oxfordshire, Det Forenede Kongerige, OX3 7LE
        • Churchill Hospital
    • South Yorkshire
      • Sheffield, South Yorkshire, Det Forenede Kongerige, S10 2JF
        • Royal Hallamshire Hospital
    • Suffolk
      • Ipswich, Suffolk, Det Forenede Kongerige, IP4 5PD
        • Ipswich Hospital
    • Surrey
      • Croydon, Surrey, Det Forenede Kongerige, CR7 7YE
        • Croydon University Hospital
      • Guildford, Surrey, Det Forenede Kongerige, GU2 7XX
        • Royal Surrey County Hospital
    • Tyne and Wear
      • Newcastle upon Tyne, Tyne and Wear, Det Forenede Kongerige, NE7 7DN
        • Freeman Hospital
    • West Midlands
      • Wolverhampton, West Midlands, Det Forenede Kongerige, WV10 0QP
        • New Cross Hospital
    • West Sussex
      • Chichester, West Sussex, Det Forenede Kongerige, PO19 6SE
        • St Richard's Hospital
      • Worthing, West Sussex, Det Forenede Kongerige, BN11 2DH
        • Worthing Hospital
    • West Yorkshire
      • Wakefield, West Yorkshire, Det Forenede Kongerige, WF1 4DG
        • Pinderfields General Hospital
    • Worcestershire
      • Kidderminster, Worcestershire, Det Forenede Kongerige, DY11 6RJ
        • Kidderminster Hospital
      • Redditch, Worcestershire, Det Forenede Kongerige, B98 7UB
        • Alexandra Hospital
      • Worcester, Worcestershire, Det Forenede Kongerige, WR5 1DD
        • Worcester Royal Hospital
    • Yorkshire
      • Leeds, Yorkshire, Det Forenede Kongerige, LS9 7TF
        • St James's University Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

16 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Written informed consent
  • NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables
  • Histologically confirmed Transitional-cell carcinoma (TCC) at original diagnosis
  • Aged 16 or over
  • Satisfactory pre-treatment haematology values and serum creatinine < 1.5 x Upper Limit of Normal (ULN)
  • Negative pregnancy test for women of child-bearing potential

Exclusion Criteria:

  • Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year since initial diagnosis or in the past five years, whichever is shorter
  • Any history of histologically confirmed non-TCC bladder cancer
  • Trial entry recurrence identified within 11.5 months of the date of the original diagnosis
  • Any prior treatment of the trial entry recurrence (including biopsy)
  • Previous MMC chemotherapy other than a single instillation at diagnostic surgery
  • Known allergy to MMC
  • Carcinoma involving the prostatic urethra or upper urinary tract (participants should have had imaging of the upper urinary tract within 2 years prior to randomisation)
  • Known or suspected reduced bladder capacity (<100ml)
  • Significant bleeding disorder
  • Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active.
  • Active or intractable urinary tract infection
  • Urethral stricture or anything impeding the insertion of a catheter
  • Large narrow neck diverticula
  • Significant urinary incontinence
  • Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
  • Unable or unwilling to comply with study procedures or follow up schedule

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Chemoresection

4 once weekly outpatient intravesical instillations 40mg Mitomycin C

Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.

Andre navne:
  • MMC
Andet: Surgical Management

Surgical management according to local practice

Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Complete response rate with chemoresection
Tidsramme: 3 months

Defined as an absence of any tumour following chemoresection and will be assessed visually at 3 month check cystoscopy by patients' urologists. A biopsy of the tumour bed would take place to confirm visual assessment of complete response.

3 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Treatment compliance in chemoresection group
Tidsramme: Duration of treatment (3 weeks)

Patients who receive 4 MMC instillations with no more than 14 days between each instillation will be described as fully compliant.

Duration of treatment (3 weeks)
Salvage surgery rates
Tidsramme: 3 years

Assessing trans-urethral resection and biopsy rates following initial treatment in both treatment groups

3 years
Progression-free survival
Tidsramme: 3 years

Defined as time from randomisation to the first of muscle invasive bladder recurrence, recurrence in the pelvic nodes, distant metastatic recurrence or death from any cause.

3 years
Toxicity (NCI Common Toxicity Criteria for Adverse Effects (CTCAE) V4 and Clavien Dindo grade (in surgical group))
Tidsramme: up to 12 months

Measuring side effects of both treatments using clinician reported toxicity scales

up to 12 months
European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) and Superficial Bladder Cancer (BLS24) questionnaire
Tidsramme: up to 12 months

Assessing side effects and impact of both treatments on patient reported quality of life.

up to 12 months
Health service utilisation
Tidsramme: up to 12 months

Assessed using prospective data collection of health resource usage.

up to 12 months
Recurrence free interval
Tidsramme: up to 12 months

Time from end of treatment to first relapse, in patients confirmed recurrence free at 3 months

up to 12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Hugh Mostafid, Royal Surrey County Hospital NHS Foundation Trust

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. oktober 2014

Primær færdiggørelse (Faktiske)

1. januar 2018

Studieafslutning (Faktiske)

21. februar 2022

Datoer for studieregistrering

Først indsendt

19. februar 2014

Først indsendt, der opfyldte QC-kriterier

21. februar 2014

Først opslået (Anslået)

25. februar 2014

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • ICR-CTSU/2013/10041
  • 2013-005095-18 (EudraCT nummer)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .